Cargando…

Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor

Tumor heterogeneity makes routine drugs difficult to penetrate solid tumors, limiting their therapy efficacies. Based on high tissue penetrability of hydrogen molecules (H(2)) and ultrasound (US) and the immunomodulation effects of H(2) and lactic acid (LA), this work proposes a novel strategy of US...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Anbang, Jiang, Lingdong, Xia, Chao, Xu, Qingqing, Zhou, Bin, Jin, Zhaokui, He, Qianjun, Guo, Jinxiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558630/
https://www.ncbi.nlm.nih.gov/pubmed/37587791
http://dx.doi.org/10.1002/advs.202303016
_version_ 1785117319326859264
author Wu, Anbang
Jiang, Lingdong
Xia, Chao
Xu, Qingqing
Zhou, Bin
Jin, Zhaokui
He, Qianjun
Guo, Jinxiao
author_facet Wu, Anbang
Jiang, Lingdong
Xia, Chao
Xu, Qingqing
Zhou, Bin
Jin, Zhaokui
He, Qianjun
Guo, Jinxiao
author_sort Wu, Anbang
collection PubMed
description Tumor heterogeneity makes routine drugs difficult to penetrate solid tumors, limiting their therapy efficacies. Based on high tissue penetrability of hydrogen molecules (H(2)) and ultrasound (US) and the immunomodulation effects of H(2) and lactic acid (LA), this work proposes a novel strategy of US‐driven piezoelectrocatalytic tumor immunoactivation for high‐efficacy therapy of deep tumors by piezoelectrocatalytic hydrogen generation and LA deprivation. A kind of US‐responsive piezoelectric SnS nanosheets (SSN) is developed to realize US‐triggered local hydrogen production and simultaneous LA deprivation in deep tumors. The proof‐of‐concept experiments which are executed on an orthotopic liver cancer model have verified that intratumoral SSN‐medicated piezoelectrocatalytically generated H(2) liberates effector CD8(+) T cells from the immunosuppression of tumor cells through down‐regulating PD‐L1 over‐expression, and simultaneous LA deprivation activates CD8(+) T cells by inhibiting regulatory T cells, efficiently co‐activating tumor immunity and achieving a high outcome of liver tumor therapy with complete tumor eradication and 100% mice survival. The proposed strategy of US‐driven piezoelectrocatalytic tumor immunoactivation opens a safe and efficient pathway for deep tumor therapy.
format Online
Article
Text
id pubmed-10558630
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105586302023-10-08 Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor Wu, Anbang Jiang, Lingdong Xia, Chao Xu, Qingqing Zhou, Bin Jin, Zhaokui He, Qianjun Guo, Jinxiao Adv Sci (Weinh) Research Articles Tumor heterogeneity makes routine drugs difficult to penetrate solid tumors, limiting their therapy efficacies. Based on high tissue penetrability of hydrogen molecules (H(2)) and ultrasound (US) and the immunomodulation effects of H(2) and lactic acid (LA), this work proposes a novel strategy of US‐driven piezoelectrocatalytic tumor immunoactivation for high‐efficacy therapy of deep tumors by piezoelectrocatalytic hydrogen generation and LA deprivation. A kind of US‐responsive piezoelectric SnS nanosheets (SSN) is developed to realize US‐triggered local hydrogen production and simultaneous LA deprivation in deep tumors. The proof‐of‐concept experiments which are executed on an orthotopic liver cancer model have verified that intratumoral SSN‐medicated piezoelectrocatalytically generated H(2) liberates effector CD8(+) T cells from the immunosuppression of tumor cells through down‐regulating PD‐L1 over‐expression, and simultaneous LA deprivation activates CD8(+) T cells by inhibiting regulatory T cells, efficiently co‐activating tumor immunity and achieving a high outcome of liver tumor therapy with complete tumor eradication and 100% mice survival. The proposed strategy of US‐driven piezoelectrocatalytic tumor immunoactivation opens a safe and efficient pathway for deep tumor therapy. John Wiley and Sons Inc. 2023-08-16 /pmc/articles/PMC10558630/ /pubmed/37587791 http://dx.doi.org/10.1002/advs.202303016 Text en © 2023 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Wu, Anbang
Jiang, Lingdong
Xia, Chao
Xu, Qingqing
Zhou, Bin
Jin, Zhaokui
He, Qianjun
Guo, Jinxiao
Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor
title Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor
title_full Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor
title_fullStr Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor
title_full_unstemmed Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor
title_short Ultrasound‐Driven Piezoelectrocatalytic Immunoactivation of Deep Tumor
title_sort ultrasound‐driven piezoelectrocatalytic immunoactivation of deep tumor
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558630/
https://www.ncbi.nlm.nih.gov/pubmed/37587791
http://dx.doi.org/10.1002/advs.202303016
work_keys_str_mv AT wuanbang ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor
AT jianglingdong ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor
AT xiachao ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor
AT xuqingqing ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor
AT zhoubin ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor
AT jinzhaokui ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor
AT heqianjun ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor
AT guojinxiao ultrasounddrivenpiezoelectrocatalyticimmunoactivationofdeeptumor